Global Harmonization Of Combination Product Regulation: EU vs US
This article was originally published in Clinica
Wherever you are in the world, the regulation of many different drug/device combination products is highly complex and costly. Yet the number of products being developed in combination is soaring. In this article, Neil O'Flaherty and Roberto Cursano, partners at law firm Baker & McKenzie, review the likelihood of global regulatory harmonization in this area, focusing on the differences between the EU and the US
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.